Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Prostatype Genomics

0.15 SEK-3.53 %21/9 11:56
Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-3.53 %
+30.87 %
-38.39 %
-56.63 %
+31.85 %
-39.14 %
-99.24 %
-99.94 %
-99.89 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
84.29M SEK
Turnover
405.57K SEK
Revenue
594K
EBIT %
-6,555.22 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
11/2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-09-17 17:20

Prostatype Genomics AB tillförs cirka 12,5 MSEK i samband med inlösen av teckningsoptioner av serie TO6

Prostatype Genomics
Regulatory press release2026-09-17 17:20

Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6

Prostatype Genomics
Regulatory press release2026-09-10 12:00

Sista dag för handel med Prostatype Genomics AB:s teckningsoptioner av serie TO6 är imorgon

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-09-10 12:00

The last day of trading in Prostatype Genomics AB’s warrants of series TO6 is tomorrow

Prostatype Genomics
Regulatory press release2026-09-01 08:45

Lösenperioden för teckningsoptioner av serie TO6 inleds idag

Prostatype Genomics
Regulatory press release2026-09-01 08:45

The exercise period for warrants of series TO6 starts today

Prostatype Genomics
Regulatory press release2026-08-31 10:40

Prostatype Genomics erhåller åtaganden och avsiktsförklaringar om cirka 70 procent av optionsinlösen TO6

Prostatype Genomics
Regulatory press release2026-08-31 10:40

Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6

Prostatype Genomics
Regulatory press release2026-08-31 09:30

Prostatype Genomics publicerar delårsrapport för det första halvåret 2026

Prostatype Genomics
Regulatory press release2026-08-31 09:30

Prostatype Genomics publishes its interim report for the first half of 2026

Prostatype Genomics
Press release2026-08-27 13:00

Nyemissioner.se: Läs om Prostatype Genomics teckningsoption TO6

Prostatype Genomics
Regulatory press release2026-08-05 20:30

Prostatype Genomics AB beslutar om riktad emission

Prostatype Genomics
Regulatory press release2026-08-05 20:30

Prostatype Genomics AB resolves on a directed issue

Prostatype Genomics
Regulatory press release2026-08-03 16:30

Prostatype Genomics AB meddelar sista dag för handel med BTU och första dag för handel med teckningsoptioner av serie TO6 och TO7

Prostatype Genomics
Regulatory press release2026-08-03 16:30

Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7

Prostatype Genomics
Regulatory press release2026-07-27 18:00

Prostatype Genomics AB offentliggör utfall i företrädesemission av units

Prostatype Genomics
Regulatory press release2026-07-27 18:00

Prostatype Genomics AB announces outcome in rights issue of units

Prostatype Genomics
Regulatory press release2026-07-21 08:00

Sista dag för teckning i Prostatype Genomics AB:s företrädesemission av units är den 23 juli 2026

Prostatype Genomics
Regulatory press release2026-07-21 08:00

Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026

Prostatype Genomics
Third party research2026-07-16 10:11

Prostatype Genomics: Lång väntan i USA - Analysguiden

Prostatype Genomics söker sedan 2024 ersättning från amerikanska Medicare vid användning av gentest på patienter med lokaliserad prostatacancer. Ett positivt besked skulle öppna för inklusion i det enda vårdsystem som betalar för denna typ av gentest...

Prostatype Genomics